Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.
The company reported sales of $2.50 billion, up 4% year over year, beating the consensus of $2.41 billion. On an organic operational basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024.
Revenue in the U.S. segment was $1.4 billion, up 4% and 7% on an organic operational basis.
Also Read: Phibro’s Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost
Sales of the company’s companion animal products increased 9%, driven primarily by Simparica Trio, the company’s flea, tick, and heartworm combination product, as well as its key dermatology portfolio, including Apoquel, Apoquel Chewable, and Cytopoint.
Broad-based growth across the remainder of the companion animal portfolio, including vaccines and diagnostics, was partially offset by a decline in the company’s monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for …